Merck Rallies to Best Year Since 1995 on Strong Sales, Drug Data
Merck & Co. notched its best yearly gain in more than two decades, making it the top-performing drugmaker in the S&P 500 in 2022 as investors rewarded the company for strong earnings and upbeat clinical trial data. • None Elon Musk Becomes First Person Ever to Lose $200 Billion • None Trump Tax…
#cantorfitzgerald #mrk #modernaincs #hpv #merckco #merck #keytruda #mizuhosecurities #cartergould #google